Xu Ping started her business career as a fund manager of an asset management company before joining Nikko antfactory K.K. (now Ant Capital Partners). While serving as Managing Partner of Ant Capital Partners, she created China investment team and took positions as the first Head of China and Asia Investment Division and established a subsidiary of Ant Capital Partners in China, Vangoo Capital Partners (Beijing) which operates the first RMB fund in Japan raised from the first class institutional investors in 2008. Xu Ping was responsible for China and Asia Investment Division, focusing on Venture Capital and Growth Capital investments in Greater China as well as real estate business development.
Xu Ping is one of famous pioneers in cross border transactions and an expert of creating investment scheme between China and Japan with more than 10 years experiences in private equity investment. She invested in more than 20 portfolio companies of consumer business, medical & health care service and energy related fields. Based on these deep knowledge and international experiences as well as strong and broad connections with business and financial industry, Xu Ping accomplished a lot of cross border alliances and advisory services of many M&A deals, such as Honma Golf and Tri-Wall Group. In 2011, Xu Ping became independent from Ant Capital Partners by acquiring Vangoo Capital Partners (Beijing) as management buy-out and have taken over whole operation of Ant Capital Partners investments in China as well as funds under management. She holds a B.A. in Economics from KEIO University, Japan. and Executive MBA of Guanghua School of Management Peking University, BeijingChina.
Doctor of Pharmacy, Master of Business Administration, a famous Japanese venture capitalist. Mr. Miyoshi worked at a leading Japanese private equity firm ANT CAPITAL, and he has more than ten years investment experiences in medical and health field, initiating investment projects with more than forty pharmaceutical and medical device companies.
Ms. Xu served as the first representative in China for "U.S. R & D and Pharmaceutical Producers Association" (PhRMA), and she worked as senior economic policy director for China R & D Pharmaceutical Industry Association (RDPAC). She worked as international finance director and director of corporate strategy for Pharmacia Corporation (Pharmacia Corporation, now Pfizer). Ms. Xu has accumulated many years of work experiences with a number of international pharmaceutical companies, in charge of international business negotiations, mergers and acquisitions and technology transfer, new product pricing and launching, and government relation, and she is a veteran of the pharmaceutical industry consultants and advisers. Ms. Xu received her Bachelors Degree in Physics from Peking University and MBA degree (Finance) from Washington University in St. Louis.
As a senior investment manager, worked in Zhuhai Financial Investment Holding Group co., LTD., focusd on TMT and consumption upgrade, had rich experience in fund management and operation.
Graduated from Shenzhen University,with master degree in technology economics and management. CPA certification (certified public accountant).
Ms. Yu worked at renowned domestic law firm. Ms. Yu is familiar with the laws and regulations on the areas of company, contract, foreign investment, real estate and etc. and has rich practical experience. Ms. Yu provided the whole process of legal services for assets transferring/equity merger and acquisition projects of the large and medium-sized enterprises, including but not limited to due diligence, deal structure designing, legal documents drafting, contract negotiating and filing with the competent authorities. She also provided legal services to many foreign enterprises for establishing the private equity fund in mainland China. Ms. Yu graduated from China University of Politic Science and Law, with master degree of law. Ms. Yu was authorized of Legal Professional Qualification in 2008.